Skip to main content

Table 5 Robustness data

From: Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

Factor Peak area
TAF COBI FTC DRV
Mean area %RSD Mean area %RSD Mean area %RSD Mean area %RSD
A. Flow rate (mL/min)
0.29 112,922 0.8 347,767 0.3 599,113 0.5 2,062,666 1.0
0.31 119,284 0.9 340,890 0.5 534,204 0.5 2,240,395 0.9
B. Mobile phase ratio (buffer:ACN)
62:38 114,571 1.2 323,011 0.9 595,532 1.1 2,037,110 0.8
58.42 113,765 0.7 363,258 0.7 545,358 0.6 1,925,353 1.0
C. Column temperature (°C)
28 113,507 0.9 324,637 0.3 544,303 0.2 1,963,363 0.9
32 104,691 1.0 353,998 0.9 568,834 0.3 2,215,824 0.5
  1. TAF tenofovir alafenamide, COBI cobicistat, FTC emtricitabine, DRV darunavir, % percentage, RSD relative standard deviation, mL/min millilitre/minute, ACN acetonitrile, oC degree Celsius